ClinicalTrials.gg
RecruitingNCT07446101Updated May 14, 2026

A Study of Mirikizumab Solution (LY3074828) in Healthy Participants

A Phase 1 interventional study of Mirikizumab in Healthy, sponsored by Eli Lilly and Company. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
450
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 15 weeks.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females as determined by medical evaluation including:

    • medical history
    • physical examination
    • clinical laboratory tests
    • , and
    • vital signs.
  • Have clinical laboratory test results at screening and Day -1 within normal reference range.
  • Have a (BMI) within the range of 18.0 to 34.0 kilograms per square meter (kg/m²), inclusive.

Exclusion criteria

Exclusion Criteria:

  • Have significant allergies to humanized monoclonal antibodies or known allergies to mirikizumab, related compounds or any components of the formulation, or history of significant atopy.
  • Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs.
  • Have multiple or severe drug allergies, or intolerance to topical , or severe post-treatment reactions.
  • Are .
  • Intend to use over-the-counter or prescription medication, including herbal medications and traditional medications, within 7 days prior to dosing.
  • Have received treatment with biologic agents within 3 months or 5 half-lives, whichever is longer, prior to dosing.
  • Have previously received mirikizumab.
  • Have an abnormality in the 12-lead (ECG).
  • Have clinically significant abnormalities in blood pressure, pulse rate, or body temperature.
  • Have a current or recent acute, active infection.
  • Have active tuberculosis (TB), or any history of active TB.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Mirikizumab (Test Arm 1)

    Mirikizumab administered subcutaneously (SC)

    Drug: Mirikizumab

  • Experimental
    Mirikizumab (Test Arm 2)

    Mirikizumab administered SC

    Drug: Mirikizumab

  • Experimental
    Mirikizumab (Reference Arm)

    Mirikizumab administered SC

    Drug: Mirikizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3074828

    Time frame: Day 1 through Day 71

  2. PK: Area Under the Concentration Versus Time Curve (AUC)(0-∞) of LY3074828

    Time frame: Day 1 through Day 71

07

Study locations

5 of 5 sites recruiting
  • Fortrea Clinical Research Unit
    Daytona Beach, Florida 32117, United States
    Recruiting
    • · Contact866-429-3700
    • Kathleen Doisy · Principal investigator
  • Axis Clinicals LLC
    Dilworth, Minnesota 56529, United States
    Recruiting
    • · Contact218-284-2947, Option 2
    • John Mickelson · Principal investigator
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
    Recruiting
    • · Contact866-429-3700
    • Archie Bowie · Principal investigator
  • Worldwide Clinical Trials, Inc.
    San Antonio, Texas 78217, United States
    Recruiting
    • · Contact210-635-1500
    • Alan Hand · Principal investigator
  • Fortrea Clinical Research Unit
    Madison, Wisconsin 53704, United States
    Recruiting
    • · Contact866-429-3700
    • Kimberly Cruz · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 3, 2026
StartActual
Mar 24, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07446101
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Mar 24, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
May 14, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion